简介:目的调查Ⅱ型糖尿病患者中糖尿病视网膜病变的患病率。方法对3055例Ⅱ型糖尿病患者进行眼部检查:包括视力、裂隙灯、眼压、散瞳孔查眼底、眼底摄片等,部分患者进行眼底荧光血管造影检查,并检测血糖、糖化血红蛋白。根据新的国际临床分级标准诊断,计算糖尿病视网膜病变患病率;并分析病程、糖化血红蛋白对患病率的影响。结果在3055例Ⅱ型糖尿病患者中经眼底镜、眼底摄片和眼底荧光血管造影检查,确诊有糖尿病视网膜病变的705例,占23.08%。其中非增生性DR者579例,占18.95%,增生性DR者126例,占4.13%;随着病程的延长其发病率显著增高;糖化血红蛋白浓度与发病率亦呈显著相关。结论Ⅱ型糖尿病患者就诊时,糖尿病视网膜病变患病率已较高。糖尿病视网膜病变患病率随糖尿病病程的延长而增加,且与糖化血红蛋白浓度呈正相关。早期及定期对糖尿病患者进行筛查为及时发现病变、把握治疗时机从而降低糖尿病视网膜病变致盲率的唯一有效方法。(中国眼耳鼻喉科杂志,2006,6:226~228)
简介:目的在视网膜缺血再灌注模型上,观察再灌注后视网膜内caspase-3的动态变化,探讨caspase-3与视网膜细胞凋亡的关系。方法结扎大鼠左侧颈总动脉1h,然后再灌注,检测再灌注后1、6、12、24、48、72h大鼠视网膜内caspase-3的水平及视网膜细胞凋亡平均发生率。结果再灌注后视网膜内caspase-3的表达出现在光感受器细胞层,在再灌注后1、6、12、24、48、72hcaspase-3平均光密度分别为0.067±0.004、0.923±0.045、1.962±0.377、3.793±0.860、2.039±0.427、1.332±0.109,细胞凋亡平均发生率(%)分别为1.8±0.1,7.1±0.2,18.2±1.4,34.7±2.1,22.6±0.9,16.3±0.4。结论再灌注后大鼠视网膜caspase-3表达与细胞凋亡呈现正相关,caspase-3可以促进视网膜细胞凋亡的发生。
简介:目的:分析玻璃体腔注射曲安奈德术后继发性青光眼的发生率和危险因素。方法:对连续收治的256例有玻璃体腔注射曲安奈德适应证的各类眼底病患者实施单次玻璃腔注射4mg/0.1mL曲安奈德手术,观察其术后眼压变化情况。主要适应证包括湿性年龄相关性黄斑变性,其它原因如糖尿病性视网膜病变、视网膜中央静脉阻塞、视网膜分支静脉阻塞,视网膜静脉周围炎等引起的黄斑水肿性疾病。结果:256例256眼经至少3mo的追踪观察随访中,56眼发生继发性青光眼,发病率为21.9%。结论:继发性青光眼与年龄、性别、血压、糖尿病、玻璃体腔注药术的不同适应证、术前是否行白内障手术、是否行光动力治疗、是否行玻璃体切除手术等因素没有相关性。注药前青光眼病史的存在和基础眼压高于19mmHg等情况为术后继发性青光眼的显著危险因素。
简介:AIM:Toinvestigatethediffusioncharacteristicsofwaterofopticnerveandopticradiationinhealthyadultsanditsrelatedfactorsbydiffusiontensorimaging(DTI)at3T.METHODS:Atotalof107healthyvolunteersperformedheadconventionalMRIandbilateralopticnerveandopticradiationDTI.TheprimarydataofDTIwasprocessedbypost-processingsoftwareofDTIstudio2.3,obtainingfractionalanisotropyvalue,meandiffusivityvalue,principalenginevalue,orthogonalenginevaluebymeasuring,andanalyzedbytheSPSS13.0statisticalsoftware.RESULTS:Thebilateralopticnerveandopticradiationfiberspresentedgreencolorindirectionalencodedcolor(DEC)mapsandpresentedhighsignalinfractionalanisotropy(FA)maps.TheFAvalueoftheleftopticnervewas0.598±0.069andtherightwas0.593±0.065;themeandiffusivity(MD)valueoftheleftopticnervewas(1.324±0.349)×10-3mm2/sandtherightwas(1.312±0.350)x10-3mm2/s;theprincipalenginevalue(λ?)oftheleftopticnervewas(2.297±0.522)×10-4mm2/sandtherightwas(2.277±0.526)×10-3mm2/s;theorthogonalenginevalue(λ⊥)oftheleftopticnervewas(0.838±0.285)×10-3mm2/sandtherightwas(0.830±0.280)×10-3mm2/s;theFAvalueoftheleftopticradiationwas0.636±0.057andtherightwas0.628±0.056;themeandiffusivity(MD)valueoftheleftopticradiationwas(0.907±0.103)×10-3mm2/sandtherightwas(0.889±0.125)×10-3mm2/s;theprincipaleigenvalue(λⅡ)oftheleftopticradiationwas(1.655±0.210)×10-3mm2/sandtherightwas(1.614±0.171)×10-3mn2/s;theorthogonalenginvalue(λ⊥)oftheleftopticradiationwas(0.531±0.103)×10-3mm2/sandtherightwas(0.524±0.152)×10-3m
简介:目的:对比分析伴虹膜异色的青光眼睫状体炎综合征与Fuchs综合征患者的临床表现及特点,对两种疾病的鉴别要点作出分析及总结,利于临床医生对这两种疾病进行鉴别诊断。方法:对本院自2000年至今收治住院的3例伴虹膜异色的青光眼睫状体炎综合征(Posner-Schlossman’ssyndrome,PSS)患者进行详细的临床检查及研究,根据其临床资料总结出该病的临床特点,并对伴虹膜异色的PSS与Fuchs综合征的鉴别要点作出分析及总结。结果:共收集了3例伴虹膜异色的PSS患者,均为单眼反复发病,病程均在10a以上,发作时眼压明显升高,可达30.00~60.00mmHg,持续时间一般为3~7d,可自行缓解或用药后缓解,间歇期眼压正常,该3例患者除了具有典型的PSS表现外,虹膜均轻度异色。总结了该病在发作期及间歇期的临床表现,从发病情况、眼压波动情况、KP形态、晶状体情况、眼底及视功能情况详细论述了伴虹膜异色的青光眼睫状体炎综合征与Fuchs综合征的区别,并针对两种疾病的治疗提出了不同建议。结论:结合我们所提出的鉴别要点,对患者进行详细的临床检查,可以对这两种疾病进行鉴别诊断。
简介:AIM:Toassesstheeffectofmyopiaonthethicknessofretinalnervefiberlayer(RNFL)measuredby3Dopticalcoherencetomography(3D-OCT)inagroupofnonglaucomatousChinesesubjects.METHODS:Twohundredandfifty-eighteyesof258healthyChinesemyopicindividualswererecruitedandfourgroupswereclassifiedaccordingtotheirsphericalequivalent(SE):lowmyopia(n=42,-0.50
简介:AIM:ToIntroduceanewspecializedvisualacuitychartforamblyopicchildrenaged3-5yearsoldanditsclinicalapplications.METHODS:ThenewvisualacuitychartandnotationsweredesignedbasedonWeber-Fechnerlaw.Theoptotypeswereredagainstawhitebackgroundandwerespeciallyshapedfourbasicgeometricsymbols:circle,square,triangle,andcross.Aregulargeometricprogressionoftheoptotypesizesanddistributionwasemployedtoarrangein14lines.Theprogressionrateoftheoptotypesizebetweentwolineswas1.2589andthetestingdistancewas3m.VisualacuityscorecouldberecordedaslogMARnotationordecimalnotation.Agestratifieddiagnosticcriteriaforamblyopiaestablishedbyconsensusstatementondiagnosisofamblyopia(2011)amongmembersoftheStrabismusandPediatricOphthalmologyGroup,OphthalmologySociety,ChineseMedicalAssociation(SPOGOSCMA)wereillustratedinthenewvisualacuitychart.RESULTS:Whenassessingvisualacuityinchildrenaged3-5yearsold,thisnewvisualacuitychartthatconsistsoffoursymmetricalshapes(triangle,square,cross,andcircle)overcameaninabilitytorecognizethelettersofthealphabetanddifficultiesindesignatingthedirectionofblackabstractsymbolssuchasthetumbling’E’orLandolt’C’,whichthesubjectswerepronetoloseinterestin.Thevisualacuityscoremayberecordedindifferentnotations:decimalacuityandlogMAR.Thesetwonotationscanbeeasilyconvertedeachotherintheneweyechart.Themeasurementsofthisnewchartnotonlyshowedasignificantcorrelationandagoodconsistencywiththeinternationalstandardlogarithmicvisualacuitychart(r=0.932,P<0.01),butalsoindicatedahightest-retestreliability(89%ofretestscoreswerewithin0.1logMARunitsoftheinitialtestscore).CONCLUSION:Theresultsofthisstudysupportthevalidityandreliabilityofdistancevisualacuitymeasurementsusingtheneweyechartinchildrenaged3to5yearsoverawiderangeofvisualacuities,andtheneweyechartisgreatforearl
简介:目的观察1,25(OH)2D3对高糖诱导牛视网膜血管内皮细胞(BRECs)中血管内皮生长因子(VEGF)的表达水平变化及对细胞凋亡水平的影响。方法将分离培养的BRECs分为三组,分别为正常糖组、高糖组和高糖处理组。正常对照组细胞培养液含5mmol/L葡萄糖,高糖组细胞培养液含30mmol/L葡萄糖,高糖处理组细胞培养液含30mmol/L葡萄糖和50nM,1,25(OH)2D3。培养48h后收集细胞蛋白。蛋白免疫印迹法检测细胞VEGF及细胞凋亡相关蛋白Bax和Bcl-2表达水平;PI/Hoechst双染色法检测细胞凋亡。结果相比于正常糖组,高糖组中VEFG水平和Bax/Bcl-2比值显著增加;而在高糖处理组中表达水平远远低于高糖组,差异均有统计学意义(P〈0.05)。高糖的细胞凋亡水平高于正常糖组,而经过1,25(OH)2D3处理后,其细胞凋亡水平则有所下降,差异均有统计学意义(P〈0.05)。结论1,25(OH)2D3可以抑制高糖诱导BRECs中VEGF表达增加及细胞凋亡。
简介:AIM:Topresenttheoutcomeofmodifiedgridlaserphotocoagulation(GLP)indiffusediabeticmacularedema(DDME)ineyeswithoutextrafovealand/orvitreofovealtraction.METHODS:InclusioncriteriafortheretrospectivestudywereDDMEeyesofpatientswithtypeⅡdiabetesmellitusthathad≥4monthsoffollow-upfollowingGLP.Onlyoneeyeperpatientwasanalyzed.Using3-Dspectral-domainopticalcoherencetomography(3-DSDOCT),eyesthathadeitherextrafovealorvitreofovealtraction,orhadbeenpreviouslytreatedbyanintravitrealmedication(s)wereexcluded.TreatedDDMEeyesweredividedinto4groups:A)'Classic'DDMEthatinvolvedthecentralmacula;B)edemadidnotinvolvethemacularcenter;C)eyesassociatedwithcentralepiretinalmembrane(ERM);D)DDMEthatwasassociatedwithmacularcapillarydropout≥2disc-diameter(DD).RESULTS:GLPoutcomein35DDMEeyesafter4-24(mean,13.1±6.9)monthswasasfollows:GroupA)18eyeswith'classic'DDME.Followingoneor2(mean,1.2)GLPtreatments,best-correctedvisualacuity(BCVA)improvedby1-2Snellenlinesin44.4%(8/18)ofeyes,andworsenedby1linein11.1%(2/18).Centralmacularthickness(CMT)improvedby7%-49%(mean,26.6%)in77.8%(14/18)ofeyes.CausesofCMTworsening(n=4)werecommonlyexplainable,predominantly(n=3)associatedwithemergenceofextrafovealtraction,5-9monthspost-GLP.GroupB)GLP(s)inDDMEthatdidnotinvolvethemacularcenter(n=6)resultedinimprovedBCVAby1-2linesin2eyes.However,thecentralmaculabecameinvolvedintheedemaprocessaftertheGLPin3(50%)eyes,associatedwithanemergenceofextrafovealtractioninoneoftheseeyes4monthsfollowingtheGLP.GroupC)GLPfailedinall5eyesassociatedwithcentralERM.GroupD)GLPwasofpartialbenefitin2of6treatedeyeswithmacularcapillarydropout≥2DD.CONCLUSION:EyeswithDDMEthatinvolvedthemacularcenterwerefoundtoachievefavourableoutcomesafterGLP(s)duringmid-termfollow-up,unlesscomplicatedpre-GLPorpost-GLPbyvltreoretinalinterfaceabnormalities,oftenextrafovealtra